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Abstract
Copy number variations (CNVs) are genomic regions that have added (duplications) or deleted (deletions) genetic material.
They may overlap genes affecting their function and have been shown to be associated with disease. We previously
investigated the role of CNVs in late-onset Alzheimer’s disease (AD) and mild cognitive impairment using Alzheimer’s
Disease Neuroimaging Initiative (ADNI) and National Institute of Aging-Late Onset AD/National Cell Repository for AD (NIA-
LOAD/NCRAD) Family Study participants, and identified a number of genes overlapped by CNV calls. To confirm the findings
and identify other potential candidate regions, we analyzed array data from a unique cohort of 1617 Caucasian participants
(1022 AD cases and 595 controls) who were clinically characterized and whose diagnosis was neuropathologically verified.
All DNA samples were extracted from brain tissue. CNV calls were generated and subjected to quality control (QC). 728 cases
and 438 controls who passed all QC measures were included in case/control association analyses including candidate gene
and genome-wide approaches. Rates of deletions and duplications did not significantly differ between cases and controls.
Case-control association identified a number of previously reported regions (CHRFAM7A, RELN and DOPEY2) as well as a new
gene (HLA-DRA). Meta-analysis of CHRFAM7A indicated a significant association of the gene with AD and/or MCI risk
(P= 0.006, odds ratio = 3.986 (95% confidence interval 1.490–10.667)). A novel APP gene duplication was observed in one
case sample. Further investigation of the identified genes in independent and larger samples is warranted.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
characterized by loss of memory and other cognitive abilities,
severe enough to disrupt daily life activities. An estimated 5.4
million Americans have AD, the sixth leading cause of death
across all ages in the United States [1]. No treatments at present
can slow or halt its progression. Amnestic mild cognitive
impairment (MCI) is a clinical condition in which a person has
memory problems not normal for his/her age, but not severe
enough to interfere significantly with daily functioning. Approx-
imately 14–18% of individuals aged 70 years and older have MCI,
and every year 10–15% of these individuals will likely progress to
dementia, particularly AD [2].
Genetic factors play a key role in AD development
accounting for approximately 58–79% of the phenotypic
variation [3]. Mutations in APP, PSEN1 and PSEN2 primarily
cause early-onset AD (age at onset,60 or 65 years) [4]. The
leading genetic risk factor for the more common late-onset AD
(age at onset.60 or 65 years) is the APOE e4 allele. Large case-
control genome-wide association studies (GWASs) have identi-
fied and replicated other AD risk loci including: CLU, CR1,
PICALM, BIN1, EXOC3L2, MTHFD1L, MS4A4A/MS4A6E,
CD2AP, CD33, ABCA7 and CUGBP2 [5–12]. However it is
estimated that the APOE e4 allele accounts for approximately
20% and the non-APOE loci cumulatively account for as much
as 35% of the AD risk [10,13]. A recent study observed only a
marginal joint effect of known loci on memory independent
from APOE [14]. The combined loci provided minimal
improvement of prediction of AD beyond age, sex and APOE.
Thus the loci do not explain all the genetic variation associated
with AD, and other forms of genetic variation such as copy
number variations (CNVs) may play a role.
CNVs are deoxyribonucleic acid (DNA) regions (one kilobase
(kb) to several megabases (Mb) in size) that have differences in
copy number. These can result in the addition (copy number
gains or duplications) or loss (copy number losses or deletions)
of genetic material. CNVs often encompass a single gene or
multiple genes and may affect their function [15]. The role of
CNVs in late-onset AD has been investigated in prior studies
[16–19]. Previously, we analyzed the role of CNVs in AD and
MCI using data from participants in the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) study [20] and the National
Institute of Aging-Late Onset AD/National Cell Repository for
AD (NIA-LOAD/NCRAD) Family Study [21]. For both
studies, DNA extracted either from peripheral blood or brain
tissue were used. Case/control association analyses including
candidate gene and genome-wide approaches were performed to
determine genes overlapped by CNVs only in cases (AD and/or
MCI) but not controls. A number of genes were identified in
the two studies including ATXN1, CHRFAM7A, CSMD1,
DOPEY2, ERBB4, GSTT1, HLA-DPB1, HNRNPCL1, IMMP2L,
NRXN1, RELN and SLC35F2.
Copy Number Variation in Alzheimer’s Disease
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e50640
The aim of the present report is to analyze the role of CNVs in
AD using data from a unique cohort of clinically characterized and
neuropathologically defined cases (AD) and controls (TGen
cohort) [22]. All DNA samples were extracted from brain tissue.
Case/control association analyses similar to the two previous
studies were performed to determine the CNV burden in cases
relative to controls and genes overlapped by CNVs detected in
cases but not controls. Here we report analyses identifying a
number of previously reported as well as new CNV regions.
Materials and Methods
Samples
The TGen cohort included samples extracted from brain tissue
of 1617 Caucasian individuals (1022 AD cases and 595 controls).
Recruitment information for the participants has been previously
described [22]. Briefly, the United States cohort was obtained
from 21 National Institute on Aging-supported Alzheimer’s
Disease Center brain banks and from the Miami Brain Bank
[23,24]. Cohorts from other brain banks in the United States,
United Kingdom, and the Netherlands were obtained similar to
the original United States cohort. Genome-wide genotyping for all
samples was performed using the Affymetrix Genome-Wide
Human SNP 6.0 Array (Santa Clara, California, United States
of America) as previously described [22]. APOE genotyping was
done using Crook et al.’s method [25] or using a fluorescence-
based allele-specific polymerase chain reaction (PCR), also called
PCR Amplification of Specific Alleles, on array tape [26] by
PreventionGenetics (Marshfield, Wisconsin, United States of
America).
The ADNI data used in the preparation of the present report
were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (http://adni.loni.ucla.edu/). ADNI’s
primary goal is to test whether imaging markers, genetic markers,
other biological markers, and clinical and neuropsychological
assessments can be combined to measure progression of MCI and
early AD. More information on ADNI can be found on http://
www.adni-info.org/. The Illumina Human610-Quad BeadChip
(San Diego, California, United States of America) was used to
perform genome-wide genotyping of the ADNI sample as
previously described [20,27]. The APOE polymorphisms
(rs429358 and rs7412) were genotyped separately.
The NIA-LOAD/NCRAD Family Study data used in the
present report were obtained from the "NIA-Late Onset
Alzheimer’s Disease and National Cell Repository for Alzheimer’s
Disease Family Study: Genome-Wide Association Study for
Susceptibility Loci" dataset (dbGaP Study Accession:
phs000168.v1.p1, Project #2026) on the database of Genotypes
and Phenotypes (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs000168.v1.p1) website. Recruitment informa-
tion for NIA-LOAD Family Study and NCRAD participants has been
previously described [12]. Genome-wide genotyping for all samples
was performed using the Illumina Human610-Quad BeadChip at the
Center for Inherited Disease Research (Baltimore, Maryland, United
States of America). The APOE polymorphisms (rs429358 and rs7412)
were genotyped at PreventionGenetics.
Ethics Statement
De-identification of samples in the TGen cohort was done
before receipt, and the study met human studies institutional
review board and the Health Insurance Portability and Account-
ability Act of 1996 regulations. The present work is declared not
human-subjects research and is institutional review board exempt
under regulation 45 CFR 46. The ADNI study was approved by
institutional review boards of all participating institutions and
written informed consent was obtained from all participants or
authorized representatives. All individuals in the NIA-LOAD/
NCRAD Family Study were recruited after providing informed
consent and with approval by the relevant institutional review
boards. The study was conducted according to the principles in the
Declaration of Helsinki.
Generation of CNV Calls and Quality Control
CNV calls were generated for the 1617 TGen samples using
PennCNV (2011Jun16 version; http://www.openbioinformatics.
org/penncnv/), a Hidden Markov model based program [28].
The PennCNV-Affy protocol (http://www.openbioinformatics.
org/penncnv/penncnv_tutorial_affy_gw6.html) for the Affymetrix
Genome-Wide Human SNP 6.0 Array was first performed to
transform raw CEL files into a signal intensity file containing the
Log R Ratio (LRR) and B Allele Frequency (BAF) values used by
PennCNV to generate CNV calls. The Hidden Markov model
‘‘affygw6.hmm’’, population frequency of B allele ‘‘af-
fygw6.hg18.pfb’’ and gcmodel ‘‘affygw6.hg18.gcmodel’’ files were
used. Extensive quality control (QC) was performed on all
samples. A genomic wave adjustment procedure using PennCNV’s
gcmodel file was applied as samples that have below optimal
genomic wave QC values can be considered unreliable [29].
Frequency distribution plots of the number of CNV calls, LRR
standard deviation (SD), BAF Drift and Waviness Factor (WF)
were made. A sample was excluded if at least one of the above
measures for the sample was greater than 90th percentile of the
frequency distribution, i.e. the sample had .56 CNV calls, LRR
SD.0.38, BAF Drift.0.01 or WF.0.02.
Due to complications of hemizygosity in males and X-
chromosome inactivation in females, analyses were restricted to
autosomes. To ensure we were including only high-confidence
CNVs in the analysis, CNVs for which the difference of the log
likelihood of the most likely copy number state and less likely copy
number state was ,10, CNVs called based on data ,10 SNPs,
and CNVs that had .50% overlap with centromeric, telomeric,
and immunoglobulin regions as defined in Need et al. [30] were
excluded. CNV calls were not filtered for size because both large
and small variants could be of potential significance. A case sample
observed to have a very large (,8.4 Mb) deletion on chromosome
19, and a control sample observed to have a very large
(,22.4 Mb) duplication on chromosome 1, were excluded from
the analyses as they may be possible outliers. The ,8.4 Mb
deletion on chromosome 19 encompassed both sides of the
centromere, but did not overlap any RefSeq or UCSC Genes
according to the UCSC Genome Browser [31] (http://genome.
ucsc.edu/). 1166 samples (728 cases, 438 controls) with 31045
CNV calls remained after all QC measures and were entered into
case/control association analyses.
Case/control Association Analyses
Case/control analyses using permutation-based tests of associ-
ation in the TGen study were performed similar to the ADNI [20]
and NIA-LOAD/NCRAD Family [21] studies. PLINK v1.07 [32]
(http://pngu.mgh.harvard.edu/˜purcell/plink/) was used to inves-
tigate CNV call differences between cases (AD) and controls. Two
approaches were used: a candidate gene approach including 317
AD genes identified from the AlzGene database (Updated 5
January 2011) (http://www.alzgene.org/) as having a positive
association with AD in at least one study, and a genome-wide
approach using 17938 genes from PLINK’s gene list (hg18
coordinates). The AlzGene database is a publicly available online
resource that provides a comprehensive and regularly updated
Copy Number Variation in Alzheimer’s Disease
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catalog of genetic case/control and family association studies in
AD [33]. In both approaches, CNV segments either partially or
completely overlapping genes were analyzed. The analyses
included both deletions and duplications. 50000 null permutations
were performed to generate one-sided empirical P values testing
genes overlapped by CNV calls in more cases than controls. The
analyses focused on genes overlapped by CNV calls in cases, but
not in controls, to identify genes that may play a role in AD
susceptibility. 317 genes were considered in the candidate gene
approach and 17938 genes were considered in the genome-wide
approach. Genes that achieved P,0.05 (one-sided) were consid-
ered significant.
Meta-analysis
We performed a meta-analysis for the CHRFAM7A gene using
results from the ADNI, NIA-LOAD/NCRAD Family and TGen
studies to determine differences in frequency of CNV calls
overlapping the gene between cases (AD and/or MCI) and
controls. A fixed-effects model was run and a summary odds ratio
(OR) was calculated using the Mantel Haenszel method.
MetaAnalyst Beta 3.13 [34] (http://tuftscaes.org/meta_analyst/
index.html) and Comprehensive Meta-Analysis Version 2 [35]
were used for the meta-analysis and generation of the forest plot
(Figure 1). The UCSC Genome Browser [31] (http://genome.
ucsc.edu/) (March 2006 (NCBI36/hg18) assembly) was used to
create representative plots of the CNV calls (Figures 2 and 3). The
Genome Browser track for the Affymetrix Genomewide 6.0 array
was obtained from the PennCNV website (http://www.
openbioinformatics.org/penncnv/penncnv_download.html).
Results
Sample Demographics and CNV Call Characteristics
The sample demographics and CNV call characteristics of the
728 cases and 438 controls who passed all QC measures are shown
in Tables 1 and 2. Significant (P,0.05; two-sided) differences in
gender, absence or presence of the APOE e4 allele, age at death,
Braak stage and the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) score were observed between cases
and controls. 31045 CNV calls (24188 deletions and 6857
duplications) were observed with an average of 45 SNPs per
CNV call and an average CNV call length of 64.76 kb. A higher
CNV call rate and a lower average CNV call size were observed in
deletions compared to duplications. Rates of deletions and
duplications did not significantly differ between cases and controls.
There were no significant differences in the rates of deletions and
rates of duplications when males and females were analyzed
separately (data not shown). A large proportion of deletions and
duplications were found in the 0.1–0.5 Mb size range (Table 3).
Case/control Association Analyses
The candidate gene approach identified 32 of the 317 genes
tested (10.09%) and the genome-wide approach identified 939 of
the 17938 genes tested (5.23%) to be overlapped by CNV calls
only in cases (AD) but not controls in the TGen study. A
significant (P=0.0003; Fisher’s exact test; two-sided) enrichment
of the candidate genes relative to the genome was observed.
Candidate gene approach. We identified 32 candidate
genes in the TGen study overlapped by CNV calls from at least
one case (AD) but no controls (Table 4). Representative plots of
two genes (APP and DOPEY2) are shown in Figure 2. The HLA-
DRA gene was overlapped by deletions in nine cases (uncorrected
P=0.0140; one-sided). This gene was also found to be overlapped
by deletions in two controls in the ADNI study. Two genes (RELN
overlapped by deletions in two cases and DOPEY2 overlapped by
duplications in four cases) identified in this study were also
reported from only cases (AD and/or MCI) in the ADNI and
NIA-LOAD/NCRAD Family studies. One AD sample (APOE e2/
e3 genotype, age at death = 67) had a novel APP gene duplication
supported by 443 sequential SNP and CNV probes. The
CHRFAM7A gene reported in the ADNI and NIA-LOAD/
NCRAD Family studies was overlapped by deletions in 10 cases
and two controls, and duplications in 12 cases and one control
(corrected P=0.0198; one-sided) in this study (Figure 3).
Genome-wide approach. We also identified 939 genes
across the genome overlapped by CNV calls only in cases (AD)
but not controls in the TGen study. Genes overlapped by CNV
calls from at least four cases but not controls in the TGen study are
shown in Table 5. The HLA-DRA gene overlapped by deletions in
nine cases in the TGen study and identified in the candidate gene
Figure 1. Forest plot of the CHRFAM7A gene. The plot represents the meta-analysis of the CHRFAM7A gene using results from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) study, the National Institute of Aging-Late Onset AD/National Cell Repository for AD (NIA-LOAD/NCRAD)
Family Study and the TGen study. The odds ratio (OR) and 95% confidence interval (CI) for the odds ratio for each study are represented by black
squares and horizontal lines. The summary odds ratio is depicted as a black diamond.
doi:10.1371/journal.pone.0050640.g001
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approach was also found from this approach (uncorrected
P=0.0144; one-sided). The CHRFAM7A gene reported in the
ADNI and NIA-LOAD/NCRAD Family Studies and mentioned
in the candidate gene approach had an uncorrected P=0.0046;
one-sided. Deletions in 10 cases and two controls, and duplications
in 12 cases and one control, overlapped the CHRFAM7A gene in
the TGen study (Figure 3). Other genes reported in the ADNI and
NIA-LOAD/NCRAD Family studies were overlapped by CNV
Figure 2. Duplications overlapping the candidate genes APP and DOPEY2 in samples of the TGen cohort. Representative UCSC Genome
Browser (March 2006 (NCBI36/hg18) assembly) plots of duplications overlapping the candidate genes: (A) APP and (B) DOPEY2, in samples of the TGen
cohort. The chromosomal location of the gene and probes on the Affymetrix Genomewide 6.0 array are shown. The region with the duplication for
each sample relative to the gene is represented by a blue rectangle.
doi:10.1371/journal.pone.0050640.g002
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calls in the TGen study although they did not reach significance at
uncorrected P,0.05. These include CSMD1 (deletions in 65 cases
and 32 controls, duplications in one case and one control), ERBB4
(deletions in 71 cases and 35 controls, duplication in one control),
HNRNPCL1 (deletions in 19 cases and eight controls, duplications
in one case and two controls), IMMP2L (deletions in six cases and
Figure 3. Deletions and duplications overlapping the CHRFAM7A gene in samples of the TGen cohort. Representative UCSC Genome
Browser (March 2006 (NCBI36/hg18) assembly) plots of deletions and duplications overlapping the CHRFAM7A gene in samples of the TGen cohort.
The chromosomal location of the gene and probes on the Affymetrix Genomewide 6.0 array are shown. The region with the deletion for each sample
relative to the gene is highlighted by a red rectangle and the region with the duplication for each sample relative to the gene is highlighted by a blue
rectangle.
doi:10.1371/journal.pone.0050640.g003
Copy Number Variation in Alzheimer’s Disease
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e50640
five controls, duplication in one control), NRXN1 (deletions in two
cases and three controls), and SLC35F2 (duplications in two cases
and one control). Deletions in three cases and three controls, and
duplications in two cases and three controls in the TGen study,
overlapped the CHRNA7 gene identified in a previous study [16].
No CNV calls were found in the TGen study overlapping other
previously reported regions including CR1 [17], 14q11.2 [18] and
15q11.2 [19].
Meta-analysis
A meta-analysis for the CHRFAM7A gene was performed using
findings from the ADNI, NIA-LOAD/NCRAD Family and TGen
studies (Table 6 and Figure 1). Overall, the gene was overlapped
by CNV calls in 38 of 1797 (2.115%) cases (AD and/or MCI) and
four of 752 (0.532%) controls. A significant association was
observed for the gene with AD and/or MCI risk (P=0.006,
summary OR=3.986 (95% confidence interval 1.490–10.667)).
Discussion
The present report represents an initial CNV analysis in the
TGen cohort, a unique cohort of clinically characterized and
neuropathologically verified individuals. After extensive QC, case
(AD)/control association analyses using candidate gene and
genome-wide approaches were performed. Genes enriched in
cases relative to controls were determined, suggesting possible
involvement of these genes in AD susceptibility.
Rates of deletions and duplications did not significantly differ
between cases and controls. This is different from findings in the
ADNI and NIA-LOAD/NCRAD Family studies and could be due
to different participant selection criteria, random sampling
variation, different QC criteria, and that the NIA-LOAD/
NCRAD Family Study and TGen study analyses included only
AD and control samples, whereas the ADNI study analyses
included MCI samples in addition to AD and control samples.
The candidate gene approach revealed a number of interesting
genes (Table 4 and Figure 2). The HLA-DRA (major histocom-
patibility complex, class II, DR alpha) gene on chromosome 6 is a
human leukocyte antigen (HLA) class II alpha chain paralogue
which plays an important role in the immune system by presenting
peptides derived from extracellular proteins. Variants in HLA-DRA
have been associated with Parkinson disease [36,37] and multiple
sclerosis [38,39], but not with AD. Other HLA alleles however
have been investigated for a possible role in AD [40–43].
The CHRFAM7A (CHRNA7 (cholinergic receptor, nicotinic,
alpha 7, exons 5–10) and FAM7A (family with sequence similarity
7A, exons A–E) fusion) gene (Figure 3) is located on chromosome
15. It is formed as a hybrid of a partially duplicated CHRNA7 gene
and the FAM7A gene [44,45]. It is highly polymorphic and
individuals with and without this gene have been identified. A 2-bp
deletion polymorphism at position 497–498 in exon 6 of this gene
has been observed to be significantly over-represented in
participants with AD, dementia with Lewy bodies and Pick’s
disease compared to controls [46].
Although CHRFAM7A is transcribed, its translation and possible
function of the resulting protein is uncertain. The gene is expressed
in the hippocampus, a brain region known to be first affected in
AD. Recently, it has been suggested to possibly modulate a7
subunit receptor-mediated synaptic transmission and cholinergic
anti-inflammatory response [47]. It may also be a dominant
negative modulator of CHRNA7 function and important for
receptor regulation in humans [48]. Duplications overlapping the
CHRNA7 gene and an approximately 300 kb region upstream of
the gene were identified in a previous study investigating the role
of CNVs in AD [16]. A meta-analysis using the CHRFAM7A gene
results from the ADNI, NIA-LOAD/NCRAD Family and TGen
studies indicated a significant association of the gene with AD
and/or MCI risk at an OR of 3.986. This association is striking
relative to known AD markers and is similar to the OR for one
copy of the APOE e4 allele. However, unlike the APOE e4 allele
which is a change in a single base within the gene, CNV calls
overlapping the CHRFAM7A gene involves more than one base
and often a large region with less than perfect definition of
boundaries given available methodology. In addition, in a CNV
analysis, a gene may be overlapped by deletions or duplications
Table 1. Sample demographics in the TGen cohort.
Cases Controls P (two-sided)
Number of samples 728 438 2
Gender (Males/Females) 180/548 274/164 ,0.001
APOE group (e4 negative/e4 positive) 93/173 138/45 ,0.001
Age at onset 72.8466.14 (n = 60) 2 2
Age at death 82.4667.58 (n = 266) 80.8069.17 (n = 183) 0.037
Braak stage 5.0960.83 (n = 168) 1.6260.76 (n = 96) ,0.001
CERADa score 2.3160.84 (n = 26) 0.8360.64 (n = 47) ,0.001
aCERAD= The Consortium to Establish a Registry for Alzheimer’s Disease.
doi:10.1371/journal.pone.0050640.t001
Table 2. Characteristics of copy number variation calls from
samples in the TGen cohort.
Cases (n =728) Controls (n =438)
Deletions
Number of copy number
variation calls
15177 9011
Rate per sample 20.85 20.57
Average size (kilobase) 45.34 46.75
Duplications
Number of copy number
variation calls
4334 2523
Rate per sample 5.95 5.76
Average size (kilobase) 140.8 131.1
doi:10.1371/journal.pone.0050640.t002
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Table 3. TGen samples grouped by copy number variation call size.
Call size (Megabase) Cases (n=728) Controls (n =438)
Deletions n (%) Duplications n (%) Deletions n (%) Duplications n (%)
0.1–0.5 647 (88.87) 625 (85.85) 387 (88.36) 368 (84.02)
0.5–1.0 95 (13.05) 164 (22.53) 61 (13.93) 101 (23.06)
1.0–1.5 10 (1.37) 25 (3.43) 7 (1.60) 12 (2.74)
1.5–2.0 4 (0.55) 7 (0.96) 0 (0.00) 2 (0.46)
.2.0 2 (0.27) 11 (1.51) 5 (1.14) 1 (0.23)
doi:10.1371/journal.pone.0050640.t003
Table 4. Genes overlapped by copy number variation calls from at least one case and no control samples in the TGen cohort using
the candidate gene approach.
Chromosome Region Start (base pair) End (base pair) Number of cases
1 FAM63A 149234172 149245957 1
1 SOAT1 177529639 177591076 1
1 AGT 228904891 228916959 1a
2 LHCGR 48767416 48836384 4a
6 HLA-G 29902734 29906878 1
6 HLA-A 30018309 30021633 2
6 HLA-E 30565249 30569072 3b
6 BAT1 31605974 31618204 1a
6 HLA-DRA 32515624 32520802 9b,c,d
6 HLA-DQB1 32735634 32742444 1c
7 MAGI2 77484309 78920826 1
7 CD36 80069439 80146529 1
7 RELN 102899472 103417198 2
8 NAT2 18293034 18303003 1
10 ALDH18A1 97355675 97406557 1
10 EBF3 131523536 131652081 1
11 PICALM 85346132 85457756 1
12 C12orf41 47333261 47362302 3
12 ALDH2 110688728 110732167 2
14 PSEN1 72672931 72756862 1
14 NGB 76801586 76807408 1d
17 SERPINF2 1592879 1605309 1
17 MYH13 10144907 10217047 2e
17 MYH8 10234366 10265992 1e
17 MAPT 41327543 41461546 1
19 GALP 61379200 61388956 1
21 APP 26174731 26465003 1
21 DOPEY2 36458708 36588442 4
21 CBS 43346369 43369493 1
21 S100B 46842958 46849463 1
22 COMT 18309308 18336530 1
22 BCR 21852551 21990224 1
aA case sample had copy number variation calls overlapping the AGT, LHCGR and BAT1 genes.
b,c,dThree different case samples had copy number variation calls overlapping the HLA-DRA and HLA-E, HLA-DRA and HLA-DQB1, and HLA-DRA and NGB genes
respectively.
eA different case sample had copy number variation calls overlapping the MYH13 and MYH8 genes.
doi:10.1371/journal.pone.0050640.t004
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which may have different effects on the protein. Nonetheless, the
strength of CNV signals overlapping the CHRFAM7A gene in the
present three samples warrants further investigation and replica-
tion in additional independent samples.
Two genes (RELN and DOPEY2) in the three studies were found
to be overlapped by CNV calls from cases (AD and/or MCI) but
not controls. The RELN (reelin) gene on chromosome 7 encodes
the glycoprotein reelin, which activates a signaling pathway
required for proper positioning of neurons within laminated
nervous system parenchyma. Gene variants have been associated
with AD [49] and the protein has been observed to have increased
expression in pyramidal neurons of the hippocampus in AD
individuals and in cognitively intact controls with AD-associated
pathology [50]. The DOPEY2 (dopey family member 2, also
known as C21orf5) gene located on chromosome 21 in the Down
syndrome critical region is a potential Down syndrome candidate
gene [51,52]. Overexpression of the gene may be associated with
the neurological phenotypes and mental retardation observed in
Down syndrome patients. Although the DOPEY2 gene was
identified in the candidate gene approach in the TGen study,
CNV calls overlapping this gene also completely overlapped the
CBR3 (carbonyl reductase 3) and CBR3-AS1 (CBR3 antisense RNA
1). The CBR3 protein, which catalyzes reduction of carbonyl
compounds to their corresponding alcohols, has been found to be
differentially expressed in the cerebellum of patients with atypical
cases of frontotemporal lobar degeneration with fused in sarcoma-
positive inclusions compared to controls [53]. Although DOPEY2 is
a known candidate, it is possible that CBR3 and CBR3-AS1 could
be pathologic given their involvement in other neurodegenerative
diseases. One AD sample (APOE e2/e3 genotype, age at
death = 67) was identified with an APP duplication. The patient
started suffering from forgetfulness at approximately 59 years and
Table 5. Genes overlapped by copy number variation calls in at least four case samples and no control samples in the TGen cohort
using the genome-wide approach.
Chromosome Region Start (base pair) End (base pair) Number of cases
1 LCE1D 151035850 151037281 6
2 GTF2A1L 48698451 48813790 4a
2 LHCGR 48767416 48836384 4a
4 TMPRSS11E2 69465107 69515259 6
6 HLA-DRA 32515624 32520802 9b
7 RP9 33100934 33115527 4
11 OR52B4 4345156 4346101 4c
11 GRM5 87880625 88420838 4
11 ST3GAL4 125731305 125789743 4c
21 CBR3 36429132 36440730 4d
21 DOPEY2 36458708 36588442 4d
22 DGCR2 17403794 17489967 5b
aFour case samples had copy number variation calls overlapping the GTF2A1L and LHCGR genes.
bA different case sample had copy number variation calls overlapping the HLA-DRA and DGCR2 genes.
cA different case sample had copy number variation calls overlapping the OR52B4 and ST3GAL4 genes.
dFour different case samples had copy number variation calls overlapping the CBR3 and DOPEY2 genes.
doi:10.1371/journal.pone.0050640.t005
Table 6. Meta-analysis of the CHRFAM7A gene.
Cohort ADNI (n =501) NIA-LOAD/NCRAD (n=882) TGen (n=1166) Overall (n = 2549)
Cases
Number of samples 358 711 728 1797
CNVa overlapping gene (n) 4 12 22 38
No CNVa overlapping gene (n) 354 699 706 1759
Controls
Number of samples 143 171 438 752
CNVa overlapping gene (n) 0 1 3 4
No CNVa overlapping gene (n) 143 170 435 748
Odds ratio 3.643 2.918 4.518 3.986
95% confidence interval 0.195–68.103 0.377–22.599 1.344–15.185 1.490–10.667
P 0.387 0.305 0.015 0.006
aCNV= copy number variation.
doi:10.1371/journal.pone.0050640.t006
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was admitted to a nursing home at approximately age 63. The
patient had no reported family history of dementia. APP
duplications have been associated with early-onset [54–57] but
not late-onset AD, and it is possible that this patient may have had
an early-onset sporadic form of AD (age at onset,60 or 65 years).
Replication in independent samples and laboratory validation can
help confirm the role of these genes in AD susceptibility.
The genome-wide approach revealed the candidate genes:
HLA-DRA and CHRFAM7A as well as identified genes reported in
the two previous studies. The CSMD1, HNRNPCL1, IMMP2L and
SLC35F2 genes have not been previously associated with AD. The
NRXN1 gene has been associated with autism [58], schizophrenia
[59], and has been shown to have reduced expression with
increasing AD severity [60]. The ERBB4 gene may play a possible
role in the progression of AD pathology [61–63].
It is important to note the limitations of the present report.
Although the same software (PennCNV) was used in the three
studies, different QC criteria were used for the selection of
samples. The ADNI and NIA-LOAD/NCRAD Family study
samples were genotyped on the Illumina Human610-Quad
BeadChip and used similar QC criteria. The TGen study samples
were genotyped on the Affymetrix Genome-Wide Human SNP
6.0 Array and thus we used a slightly different QC criteria. To our
knowledge, there does not appear to be consensus on a well
defined set of QC criteria for inclusion of the most appropriate
samples in CNV analyses. The QC criterion applied in the present
study may have been too stringent, leading to samples possibly
having informative CNV data being excluded. A direct compar-
ison of CNV calls from the three studies would be difficult as two
different genotyping platforms were used. Probes from the two
platforms may not correspond with each other with respect to their
location. Replication in additional independent data sets and
future molecular studies will help confirm the findings.
In sum, we have conducted an initial CNV analysis in samples
from a cohort of clinically characterized and neuropathologically
verified individuals. Rates of deletions and duplications did not
significantly differ between cases and controls. Gene-based
association analysis identified a number of genes including those
reported in the ADNI and NIA-LOAD/NCRAD Family studies
(CHRFAM7A, RELN and DOPEY2) as well as a new gene (HLA-
DRA). Meta-analysis from the three studies revealed a significant
association for CHRFAM7A with AD and/or MCI risk. Replica-
tion in independent samples will be necessary to confirm these
findings. Targeted analyses of the identified regions will help
determine the biological role of these variants. Overall, there
appears to be some consistency of CNVs across AD cohorts and
this variation holds promise for revealing novel risk factors and
disease mechanisms.
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